ARBs in Cardiovascular Disease
|
|
- Clyde French
- 5 years ago
- Views:
Transcription
1 ARBs in Cardiovascular Disease Yong-Jin Kim, MD Seoul National University Hospital
2 Cardiovascular Continuum Ventricular remodelling Remodelling Myocardial infarction Myocardial infarction Ventricular dilation Ventricular Dilation 2 Heart Failure Heart failure Atherosclerosis Atherosclerosis and LVH and LVH 1 End-stage Heart Disease End-stage heart disease Risk factors Diabetes Hypertension Risk factors Diabetes Hypertension 3 Death Death 1. Julius et al. Lancet 2004; 363: ; 2. Pfeffer et al. N Engl J Med 2003;349: Cohn et al. N Engl J Med 2001; 345: ; 4. Sawada et al. Eur Heart J 2009;30: Califf et al. Am Heart J 2008;156:623 32; 6. Mochizuki et al. Lancet 2007;369:1431 9
3
4 Clinical trials with ACE inhibitors Vascular and CAD HOPE, PEACE EUROPA MI CONSENSUS, ISIS-4, GISSI-4 SMILE, SAVE AIRE, TRACE Myocardial Infarction Pathological Remodeling CAD Ventricular Enlargement Atherosclerosis Hypertrophy Risk Factors: Diabetes Hypertension Hyperlipidemia Hypertension CAPPP, ALLHAT DM ABCD, REIN, AASK HF SOLVD V-HeFT II SAVE, ATLAS Heart Failure Death
5 Plasma A II (pg/ml) Plasma ACE (nmol/ml/min) AII escape with ACEI therapy Enalapril 20mg * * * * * * * * * 0 Placebo 4h 24h Hospital Months *P < vs placebo. Adapted with permission from Biollaz J et al. J Cardiovasc Pharmacol. 1982;4:
6 Clinical trials with ARB DM/Renal RENAAL, IDNT IRMAII, MARVAL ABCD-2V, NAVIGATOR Myocardial Infarction Pathological Remodeling CAD/MI VALIANT, OPTIMAL VAL-PREST CAD, Nephropathy Atherosclerosis Hypertrophy Ventricular Enlargement Heart Failure Risk Factors: Diabetes Hypertension Hyperlipidemia Hypertension VALUE, SCOPE, TROPHY, LIFE HF ELITE I&II Val-HeFT CHARM Death
7 Number of patients Angiotensin Receptor Blockers Have a Wealth of Outcomes Data 60,000 50,000 40,000 30,000 20,000 10, , , , VALUE 2. VALIANT 3. NAVIGATOR 4. Val-HeFT 5. JIKEI HEART 6. KYOTO HEART 7. VART 36, VALISH* 9. NAGOYA-HEART* 10. V-CARD* 11. ONTARGET 12. PRoFESS 13. TRANSCEND 14. HALT-PKD* 15, NCT * 16. LIFE 17. OPTIMAAL 18. ELITE II 19. RENAAL 20. NCT * 21. VA NEPHRON-D* 22. CHARM 23. SCOPE 24. SCAST* 25. CASE-J 26. ACCOST 6, HIJ-CREATE 28. E-COST 29. HOPE-3* 30. 4C* 31. I-PRESERVE 32. IDNT 33. ACTIVE-I* 34. NID SUPPORT* 36. COLM* 37. OSCAR* 38. ORIENT 39. MOSES 1,405 Diovan Telmisartan Losartan Candesartan Irbesartan Olmesartan Eprosartan *Expected enrolment Ongoing and completed randomized controlled trials with death or hard CV events as or part of the primary endpoint Valid as of December Julius et al. 2004; 2. Pfeffer et al. 2003; 3. Califf et al 2008; 4. Cohn et al. 2001; 5. Mochizuki et al. 2007; 6. Sawada et al 2009; 7. Narumi et al [abstract at ESC]; 8. (NCT ); 9. (NCT ); (NCT ); 11. ONTARGET Investigators 2008; 12. Yusuf et al 2008; 13. TRANSCEND Investigators 2008; (NCT ); (NCT ); 16. Dahlöf et al. 2002; 17. Dickstein et al. 2002; 18. Pitt et al. 2000; 19. Brenner et al. 2001; (NCT ); 21. Fried et al 2009; 22. Pfeffer et al 2003; 23. Papademetriou et al. 2004; (NCT ); 25. Ogihara et al. 2008; (NCT ); 27. Laufs et al. 2008; 28. Suzuki et al. 2005; (NCT ); (NCT ); 31. Massie et al 2008; 32. Lewis et al. 2001; (NCT ); (NCT ); (NCT ); 36. Ogihara et al 2009; 37. Ogawa et al 2009; 38. Imai et al (Abstract F-FC313 at ASN 2009); 39. Schrader et al. 2005
8 ARBs in CHF ELITE II Val-HeFT CHARM Losartan 50 OD vs Captopril 25 tid Valsartan BID add on Standard Tx vs Standard Tx Candesartan 8-32 OD add on Stardard Tx vs Standard Tx N 3,152 5,010 7,601 Primary endpoint All-cause mortality: NS All-cause mortality: NS All-cause mortality: NS No Approved Indication All-cause M/M: - Overall population : ACEI+ARB = -13.2% - Subgroup w/o ACEI: ARB = -44.5% Approved Indication CV death or HF hospitalization: - CHARM Added: ACEI+ARB = -15% - CHARM Alternative: ARB = -30% - CHARM Preserved: NS Approved Indication
9 Evolution of HF management Ancient Compensatory Hemodynamic Neurohormonal Cupping & leaching Rotating tourniquets Phlebotomy Trephine Vasodilators ACEIs -blockade ARBs 1555 B.C A.D s 1970s Symptom improvement 1990s Survival improvement 9
10 Val-HeFT: valsartan added to usual therapy for HF 5,010 HF patients >18 yr; EF <40%; NYHA II-IV Randomized to Valsartan 40 mg bid titrated to 160 mg bid Placebo 906 deaths (events recorded) Cohn et al. J Card Fail 1999;5:
11 Survival probability (%) Kaplan-Meier analysis of survival 1.0 Valsartan p = Placebo Cohn et al. NEJM 2001;345:1667 Time since randomization (months)
12 Val-HeFT: Effect of Valsartan on Combined Mortality and Morbidity End Point* Probability of Event- Free Survival Months Valsartan (n = 2511) Placebo (n = 2499) 13.2% risk reduction P = *All-cause mortality, sudden death with resuscitation, hospitalization for worsening heart failure, or therapy with IV inotropes or vasodilators. Cohn JN et al. N Engl J Med. 2001;345:
13 Event-free probability Primary endpoint: greatest benefits in patients not on ACE inhibitor therapy Combined all-cause mortality / morbidity % risk reduction p = Placebo (n = 181) Valsartan (n = 185) Time since randomization (months) Cohn et al. AHA Scientific Sessions 2000
14 Probability of Event-Free Survival Val-HeFT: AT 1 -Receptor Blockers Reduce Mortality in ACE Inhibitor Intolerant Patients Combined Morbidity/Mortality Valsartan (n = 185) Placebo (n = 181) % risk reduction 50 P = Months Mortality 33.1% risk reduction P = Months Valsartan significantly reduced all-cause mortality in a subgroup (n = 366) of ACE inhibitor intolerant CHF patients Adapted from Maggioni AP et al. J Am Coll Cardiol. 2002;40(8):
15 CHARM Programme 3 component trials comparing candesartan to placebo in patients with symptomatic heart failure CHARM Alternative n=2028 LVEF 40% ACE inhibitor intolerant CHARM Added n=2548 LVEF 40% ACE inhibitor treated CHARM Preserved n=3025 LVEF >40% ACE inhibitor treated/not treated Primary outcome for each trial: CV death or CHF hospitalisation Primary outcome for Overall Programme: All-cause death 15
16 CHARM-Alternative: Primary outcome CV death or CHF hospitalisation % Placebo 406 (40.0%) 334 (33.0%) 30 Candesartan Number at risk HR 0.77 (95% CI ), p= Adjusted HR 0.70, p< years Candesartan Placebo
17 CHARM-Alternative Secondary outcomes Candesartan Placebo CV death CHF hosp CV death, CHF hosp, MI CV death, CHF hosp, MI, stroke CV death, CHF hosp, MI, stroke, revasc p-value < candesartan better Hazard ratio placebo better 17
18 CHARM-Added: Primary outcome CV death or CHF hospitalisation % Placebo 538 (42.3%) 483 (37.9%) 30 Candesartan Number at risk HR 0.85 (95% CI ), p=0.011 Adjusted HR 0.85, p= years Candesartan Placebo
19 CHARM-Added Secondary outcomes Candesartan Placebo CV death CHF hosp CV death, CHF hosp, MI CV death,chf hosp, MI, stroke CV death,chf hosp, MI, stroke, revasc p-value candesartan better Hazard ratio placebo better 19
20 CHARM-Preserved: Primary outcome CV death or CHF hospitalisation % Placebo Candesartan 366 (24.3%) 333 (22.0%) 5 0 Number at risk HR 0.89 (95% CI ), p=0.118 Adjusted HR 0.86, p= years Candesartan Placebo
21 i-preserve: Entry Criteria Age 60 years Current HF symptoms LVEF 0.45 NYHA class II - IV CHF hosp. 6 months NYHA Class III/IV CXR congestion ECG (LVH, LBBB) Echo (LVH, LAE) Key Exclusions: SBP >160 mm Hg; prior EF <40%; ACS or stroke 3m; hypertrophic or restrictive CM, pericardial or valvular disease; significant pulmonary disease, creatinine >2.5mg/dl, Hb <11g/dL Only 1/3 pts could enter on an ACEI at baseline LBBB = left bundle branch block LAE = left atrium enlargement CHF = congestive heart failure 21
22 i-preserve: Study Design Randomized, double-blind, placebo controlled trial Irbesartan (mean dose 275 mg) N=4, mg 150 mg 300 mg (n=2,067) Enrollment Single-blind 2 weeks R Forced titration Maintenance (n=2,061) W 2 W 4 W 8 M 6 M 10 M 14 to end Every 4 months Placebo Follow-up continued until 1,440 primary endpoints occurred 22
23 Cumulative Incidence of Primary Events (%) i-preserve: Primary Endpoint Death or protocol specified CV hospitalization (Mean follow-up 49.5 months) HR (95% CI) = 0.95 ( ) Log-rank p=0.35 Placebo Irbesartan No. at Risk Irbesartan Placebo Months from Randomization
24 ARBs in Post MI OPTIMAAL VALIANT Captopril vs. Losartan Captopril vs. Valsartan vs. Combination N 5,477 14,703 Primary endpoint: All-cause mortality Captopril vs. Losartan RR 1.13 (95% CI; ) p = Valsartan vs. Captopril: HR = 1.00; P = Valsartan + Captopril vs. Captopril: HR = 0.98; P = Conclusion Study revealed that losartan was not superior to captopril, and losartan was not shown to be equivalent to captopril No Approved Indication Valsartan is as effective as a proven dose of captopril in reducing the risk of: - Death - CV death or nonfatal MI or heart failure admission Approved Indication
25 Probability of Event SAVE Radionuclide EF 40% AIRE Clinical and/or radiographic signs of HF All-Cause Mortality TRACE Echocardiographic EF 35% Placebo ACE-I Placebo: 866/2971 (29.1%) ACE-I: 702/2995 (23.4%) OR: 0.74 ( ) Years ACE-I Placebo Flather MD, et al. Lancet. 2000;355:
26 Events (%) SAVE Radionuclide EF 40% AIRE Clinical and/or radiographic signs of HF TRACE Echocardiographic EF 35% 40 ACE-I (n = 2995) Death and Major CV Events Placebo (n = 2971) 0.75* ( ) * ( ) 0.80* ( ) 10 0 n = 355 n = 460 Readmission for HF n = 324 n = 391 Reinfarction n = 1049 n = 1244 Death/MI or Readmission for HF *odds ratio (95% CI) Flather MD, et al. Lancet. 2000;355:
27 Acute MI ( days) SAVE, AIRE or TRACE eligible (either clinical/radiologic signs of HF or LV systolic dysfunction) Major Exclusion Criteria: Serum creatinine > 2.5 mg/dl BP < 100 mm Hg Prior intolerance of an ARB or ACE-I Nonconsent double-blind active-controlled Captopril 50 mg tid (n = 4909) Valsartan 160 mg bid (n = 4909) Captopril 50 mg tid + Valsartan 80 mg bid (n = 4885) median duration: 24.7 months event-driven Primary Endpoint: All-Cause Mortality Secondary Endpoints: CV Death, MI, or HF Other Endpoints: Safety and Tolerability
28 Probability of Event Mortality by Treatment Captopril Valsartan Valsartan + Captopril Valsartan vs. Captopril: HR = 1.00; P = Valsartan + Captopril vs. Captopril: HR = 0.98; P = Months Captopril Valsartan Valsartan + Cap Pfeffer, McMurray, Velazquez, et al. N Engl J Med 2003;349
29 All-Cause Mortality: Non-Inferiority Analyses Hazard Ratio (97.5% CI) noninferior ity margin P-value (noninferiority) Intention-to-Treat Patient Population (n = 14,703) Per Protocol Patient Population (n = 14,285) Noninferiority Noninferiority not Demonstrated Val Superior to Cap Cap Superior to Val Favors Valsartan Favors Captopril
30 Mortality in SAVE, TRACE, AIRE, and VALIANT SAVE Hazard Ratio for Mortality TRACE AIRE Combined VALIANT (imputed placebo) Valsartan preserves 99.6% of mortality benefit of captopril. 0.5 Favors 1 Favors 2 Active Drug Placebo Pfeffer, McMurray, Velazquez, et al. N Engl J Med 2003;349
31 Probability of Event CV Death, MI, or HF by Treatment 0.4 Captopril 0.3 Valsartan Valsartan + Captopril Valsartan vs. Captopril: HR = 0.96; P = Months 0 Valsartan + Captopril vs. Captopril: HR = 0.97; P = Pfeffer, McMurray, Velazquez, et al. N Engl J Med 2003;349
32 ARBs in High CV risk ONTARGET TRANSCEND N 25,620 5,926 Primary endpoint: CV death, MI, stroke, CHF hosp ONTARGET (N=25,620) Telmisartan vs. Ramipril RR 1.01 ( ), p = 0.02 Telmisartan + Ramipril vs. Ramipril RR 0.99 ( ) The ONTARGET Trial Programme (N=31,546) ACEI intolerant patients TRANSCEND (N=5,926) Telmisartan vs. Placebo HR=0.92 ( ), P= Conclusion In patients who have vascular disease or high-risk diabetes but do not have HF, Telmisartan is as effective as Ramipril There is no additional advantage(and there is some harm) from the combination of Telmisartan and Ramipril compared with Ramipril alone. Telmisartan was well tolerated in patients unable to tolerate ACE inhibitor. Although the drug had no significant effect on primary outcome of this study
33 ACEI in reducing CV mortality and morbidity The HOPE study % risk reduction ramipril (n=4,645) vs placebo (n=4,652) in preventing major CV events in high-risk pt 0 Composite Death from CV endpoint* CV causes MI Stroke % 26% 20% 32% 12 p<0.001 p<0.001 p<0.001 p< Ramipril, n=4,645 Placebo, n=4,652 * Composite CV endpoint = death from CV causes + MI + stroke ACE = angiotensin-converting enzyme; CV = cardiovascular; HOPE = Heart Outcomes Prevention Evaluation; MI = myocardial infarction Yusuf S, et al. N Engl J Med 2000;342:
34 mmhg LIFE: Comparable BP Reductions Systolic Mean Arterial Diastolic * Mean BP at last visit Dahlöf B et al Lancet 2002;359: Study Month Atenolol mmhg* Losartan mmhg* Atenolol mmhg* Losartan mmhg* Losartan 81.3 mmhg* Atenolol 80.9 mmhg*
35 Proportion of patients with first event (%) LIFE: Primary Composite Endpoint Composite of CV death, stroke and MI Atenolol 10 Losartan Number at Risk 2 Adjusted Risk Reduction Unadjusted Risk Reduction 13.0%, p= %, p= Losartan Atenolol Dahlöf B et al Lancet 2002;359: Study Month
36 Proportion of patients with first event (%) LIFE: Stroke Fatal and nonfatal stroke Atenolol 5 4 Losartan 3 2 Number at Risk 1 Adjusted Risk Reduction 24.9%, p=0.001 Unadjusted Risk Reduction 25.8%, p= Study Losartan Month 925 Atenolol Dahlöf B et al Lancet ;359:
37 ONTARGET: Telmisartan is as protective as ramipril in CV protection Reduction in composite CV risk Composite CV risk = cardiovascular mortality + non-fatal myocardial infarction + hospitalisation for congestive heart failure + non-fatal stroke The ONTARGET Investigators. N Engl J Med 2008;358:
38 Telmisartan 80mg as effective as ramipril 10mg in reducing CV risk CV Death MI Stroke CHF Hosp All Death Telmisartan better Ramipril better RR (95% CI)
39 Telmisartan 80mg added to ramipril 10mg: as effective as ramipril alone Reduction in composite CV risk Composite CV risk = cardiovascular mortality + non-fatal myocardial infarction + hospitalisation for congestive heart failure + non-fatal stroke The ONTARGET Investigators. N Engl J Med 2008;358:
40 VALUE: Design Rollover from previous therapy (92%) Elective titration to target BP (<140/90 mm Hg) Valsartanbased regimen V 80 mg A 5 mg Amlodipinebased regimen V 160 mg A 10 mg V 160 mg + HCTZ 12.5 mg A 10 mg + HCTZ 12.5 mg V 160 mg + HCTZ 25 mg A 10 mg + HCTZ 25 mg V 160 mg + HCTZ 25 mg + "Free" add-on A 10 mg + HCTZ 25 mg + "Free" add-on Month * 72 Screening Randomisation *Patient visits every 6 months for months Julius S et al. Lancet. June 2004;363. End of treatment adjustment period SNUH Cardiovascular Center
41 Proportion of Patients With First Event (%) VALUE: Primary Composite Cardiac Endpoint Valsartan-based regimen Amlodipine-based regimen HR = 1.03; 95% CI = ; P = 0.49 Number at risk Valsartan Amlodipine 7596 Julius S et al. Lancet. June 2004; Time (months)
42 New-onset Diabetes (% of Patients in Treatment Group) VALUE: Incidence of New-onset Diabetes (Not Prespecified in Design Paper) Julius S et al. Lancet. June 2004; % Risk Reduction With Valsartan P< % Valsartan-based Regimen (n=5094) 16.4% Amlodipine besylatebased Regimen (n=5074)
43 Possible Mechanisms of ARB in AF Prevention Inflammation Atrium: Angiotensin Collagen Synthesis LVEDP Pressure Dilatation Remodeling Fibrosis Conduction Δ AF Systemic BP SNUH Cardiovascular Center
44 Clinical Evidence: ARB 제제의심방세동예방효과 Aksnes TA et al., J Hypertens 2007;25:15-23 SNUH Cardiovascular Center
45 심방세동발생률을보고한대규모고혈압연구 대상 환자수 약제 관찰 기간 발생률 RR 감소율 LIFE 8851 Losartan Vs. Atenolol 4.8 년 3.5% Vs. 5.3% 33% (p<0.001) VALUE Valsartan Vs. Amlodipine 4.2 년 3.67% Vs. 4.34% 16% (p=0.044) LIFE study: Watchtell K et al., JACC 2005;45: VALUE trial: Schmieder R et al., J Hypertens 2006;24 (Suppl):S3 SNUH Cardiovascular Center
46 Proportion of patients with first event (%) LIFE: New Onset AF 8 7 RR: 0.67 [95% CI: ], p<0.001 Adjusted RR: 0.67 [95% CI: ], p< Time (months) Atenolol (n=4182) Losartan (n=4298) Wachtell K, et al. JACC, 2005;45:712-9 SNUH Cardiovascular Center
47 VALUE Trial: Reduced Incidence of New AF with ARB Incidence of new onset AF 3.67% in the valsartan 4.34% in the amlodipine Odds ratio 0.84 [95% CI: ], p=0.044 Incidence of persistent AF 1.35% in the valsartan 1.97% in the amlodipine Odds ratio [95% CI: ], p=0.005 Schmieder R et al., J Hypertens 2006;24 (Suppl):S3 SNUH Cardiovascular Center
48 Prevention of AF with ACEI & ARB: Meta-Analysis Healey et al. JACC 2005;45: SNUH Cardiovascular Center
49 Prevention of AF with ACEI & ARB: Meta-Analysis Healey et al. JACC 2005;45: SNUH Cardiovascular Center
50 ARBs in DN RENAAL IDNT Losartan vs Placebo Irbesartan vs Amlodipine vs Placebo N 1,513 1,715 Primary endpoint: The composite of a doubling of the base-line serum creatinine concentration, ESRD, or death Risk reduction 16%, p=0.02 Irbesartan vs Placebo RR=0.80(95%CI ), P=0.02 Amlodipine vs Placebo RR=1.04(95%CI ), P=0.69 Irbesartan vs Amlodipine RR=0.77(95%CI ), P=0.006 Conclusion Losartan conferred significant renal benefits in patients with T2DM and nephropathy Approved Indication Irbesartan is effective in protecting against the progression of nephropathy due to T2DM Approved Indication
51 Survival (all-cause mortality) Proteinuria: Independent Risk Factor for Mortality in Type 2 Diabetes Normoalbuminuria (n=191) Microalbuminuria (n=86) Macroalbuminuria (n=51) 0.5 Gall, MA et al. Diabetes 1995;44: Years P<0.01 normo vs. micro- and macroalbum P<0.05 micro vs. macroalbuminuria
52 Incidence (%) CV Outcomes and Renal Disease * Primary outcome Total mortality Mann J. et al. Ann Intern Med 2001;134:629 * * CV mortality Cr (cl) >65 ml/min (n=5888 Cr (cl) 65 ml/min (n= MI 12.5 * * Hospitalization for CHF *P<0.05. Combined CV death, MI, or stroke.
53 Angiotensin II Induced Renal Fibrosis Ang Il Renal Cells (mesangial, tubuloepithelial interstitial fibroblasts) Inflammatory Cells Growth factors: TGFß, PDGF, CTGF Cytokines: IL-6, TNFa Chemokines: MCP-1, RANTES, OPN Other: PA1, Metalloproteinases Activation and recruitment of inflammatory cells Chemotaxis Chemokines - MCP-1, RANTES Adhesion molecules - VCAM-1 Cytokines, growth factors ECM production and degradation Proteinuria ECM accumulation Cell proliferation Inflammation Renal Fibrosis Mezzano, S.A. Hypertension 2001; 38(2)
54 % with event % with event % with event RENAAL TIIDM with Nephropathy Doubling of Serum Creatinine ESRD Risk Reduction: 28% p=0.002 P L Risk Reduction: 25% p= Months P (+ CT) L (+ CT) Brenner BM et al New Engl J Med 2001;345(12): P L Months P (+ CT) L (+ CT) ESRD or Death Risk Reduction: 20% p= Months 48 P (+ CT) L (+ CT) P L
55 Median Percent Change RENAAL: Change of Proteinuria P p< % Overall Reduction L Months P (+CT) L (+CT) Proteinuria measured as the urine albumin:creatinine ratio from a first morning void. Brenner BM et al New Engl J Med 2001;345(12):
56 Proportion With Primary End Point IDNT: Cumulative Proportions of Patients With the Primary Composite End Point* Irbesartan, 300 mg (n=579) Amlodipine, 10 mg (n=567) Placebo (n=569) Relative Risk Reductions Irbesartan vs placebo: 20% (P=.02) Irbesartan vs amlodipine: 23% (P=.006) Amlodipine vs placebo: NS Months of Follow-up 1,715 patients with HTN, DM II and proteinuria > 900 mg/d for 2 year follow-up *Composite of the doubling of baseline SCr, onset of ESRD, or death from any cause. The end point difference was driven by differences in doubling of SCr and ESRD; there was no difference in mortality. Lewis et al. N Engl J Med. 2001;345:
57 Incidence of Diabetic Nephropathy (%) IRMA Placebo 150 mg of irbesartan 300 mg of irbesartan 44% Risk reduction 68% * Risk reduction Adapted from Parving, HH et al. NEJM 2001;345: Months of Follow-up *P<0.001 vs. placebo
58 New-Onset DM With RAS Blockade 0 Lisinopril (ALLHAT) Ramipril (HOPE) Losartan (LIFE) Candesartan (SCOPE) Valsartan (VALUE) Candesartan (CHARM) -10 % Reduction in New-Onset DM ALLHAT Officers and Collaborators. JAMA. 2002;288: Yusuf S et al. JAMA. 2001;286: Dählof B et al. Lancet. 2002;359: Lithell H et al. J Hypertens. 2003;21: Julius S et al. Lancet. 2004;363: Pfeffer MA et al. Lancet. 2003;362:
59 Regression of Left Ventricular Hypertrophy Meta-Analysis of 80 Studies Involving 3767 Patients With Equivalent Blood Pressure Lowering 0-2 Beta blockers Diuretics CCBs ACEIs ARBs -4 % Reduction in Left Ventricular Mass Index *P<0.05 vs beta-blockers. Klingbeil AU et al. Am J Med. 2003;115: * -10 * -13 *
60 BP-Lowering Treatment Trialists: ARB vs Other Outcome Favors ARB Favors Other RR (95% CI) Stroke 0.79 (0.69, 0.90) CHD 0.96 (0.85, 1.09) Heart failure 0.84 (0.72, 0.97) Major CV events 0.90 (0.83, 0.96) CV death 0.96 (0.85, 1.08) Total mortality 0.94 (0.86, 1.02) Relative Risk Blood Pressure Lowering Treatment Trialists Collaboration. Lancet. 2003;362:
61 Clinical trials with ARB DM/Renal RENAAL, IDNT IRMAII, MARVAL ABCD-2V, NAVIGATOR Myocardial Infarction Pathological Remodeling CAD/MI VALIANT, OPTIMAL VAL-PREST CAD, Nephropathy Atherosclerosis Hypertrophy Ventricular Enlargement Heart Failure Risk Factors: Diabetes Hypertension Hyperlipidemia Hypertension VALUE, SCOPE, TROPHY, LIFE HF ELITE I&II Val-HeFT CHARM Death
62
Cardiac Protection across the cardiac continuum. Dong-Ju Choi, MD, PhD College of Medicine Seoul National University
Cardiac Protection across the cardiac continuum Dong-Ju Choi, MD, PhD College of Medicine Seoul National University Renin Angiotensin Cascade Nitric oxide (NO) Bradykinin Degradation products ACE ACEI
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationA Fresh Look at ARBs : Focus on HF survival data
A Fresh Look at ARBs : Focus on HF survival data Seok-Min Kang, MD, Ph D. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea HF specialists ARBs,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationComprehensive Cardiovascular & Metabolic Protection Liking Scientific Advances to Clinical Practice 인제의대상계백병원 당뇨병센터 고경수
Comprehensive Cardiovascular & Metabolic Protection Liking Scientific Advances to Clinical Practice 인제의대상계백병원 당뇨병센터 고경수 Cardiovascular & metabolic risk factors The importance of BP management for HTN patients
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationΦαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.
Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationRenin Angiotensin System Current and Potential Targets
Renin Angiotensin System Current and Potential Targets Dae Suk Han, MD. Seung Hyeok Han, MD. Department of Internal Medicine Division of Nephrology Yonsei University College of Medicine Renin The First
More informationFerrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationACE inhibitors vs ARBs Myths and Facts
ACE inhibitors vs ARBs Myths and Facts Prof. Dr. med. Frank Ruschitzka, FRCP (Edinburgh) Director Heart Failure/Transplantation Clinic University Clinic Zurich Switzerland Conflict of interest: Bayer,
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationManagement of The Patients with Hypertension and High Risk Cardiovascular Disease
Management of The Patients with Hypertension and High Risk Cardiovascular Disease Songsak Kiatchoosakun, MD. Cardiology, Medicine Khon Kaen University CVD and Hypertension: Worldwide Morbidity and Mortality
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationThe Role of ACEI and ARBs in AF prevention
The Role of ACEI and ARBs in AF prevention Dr. Sameh Shaheen MD, FESC Prof. of cardiology Ain-Shams university Time course of atrial substrate remodeling in relation to the clinical appearance of AF and
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationAngiotensin Receptor Blockers: Novel Role in High-Risk Patients
Angiotensin Receptor Blockers: Novel Role in High-Risk Patients UsmanJaved, MD a, Prakash C. Deedwania, MD, FACC, FACP, FCCP, FAHA a,b, * KEYWORDS Angiotensin receptor blockers RAAS blockade Cardioprotection
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationCaring for Australians with Renal Impairment. BP lowering and CVD
Caring for Australians with Renal Impairment BP lowering and CVD Questions: Conflicts of Interest: RH, TN, HHL- no conflict VP- level II conflict Speakers fees: Abbott, Astra Zeneca, Roche, Servier Grant
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationΗ θέση της αντισπερτασικής αγωγής στην πρόληψη της κολπικής μαρμαρσγής. Ανδρέας Πιηηαράς. Σεμινάριο ΟΕ ΕΚΕ Θεζζαλονίκη 2012
Η θέση της αντισπερτασικής αγωγής στην πρόληψη της κολπικής μαρμαρσγής Ανδρέας Πιηηαράς Σεμινάριο ΟΕ ΕΚΕ Θεζζαλονίκη 2012 AF May Present with a Wide Range of Symptoms LIGHT- HEADEDNESS PALPITATIONS SYNCOPE
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationValsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University
Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationAmlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management
Amlodipine/Valsartan (Exforge ) Changing the Landscape of BP Management Bum-Kee Hong Yongdong Severance Hospital Yonsei University College of Medicine Rationale for Multiple-Mechanism Therapy Inadequacy
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationScottish Medicines Consortium
Scottish Medicines Consortium valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan ) No. (162/05) Novartis Pharmaceuticals New Indication: following myocardial infarction in patients with clinical
More informationKDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4
KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationEfficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis
Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis Dipak Kotecha, MD PhD on behalf of the Selection of slides presented at the European
More informationTwo landmark clinical trials, CONSEN-
Heart 2001;86:97 103 HEART FAILURE Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction John J V McMurray Clinical Research Initiative in Heart Failure, Wolfson Building,
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationEffects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme Inhibitors
Journal of the American College of Cardiology Vol. 40, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02304-5
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationProgress and Promise in RAAS Blockade
Progress and Promise in RAAS Blockade Overview Scope of the problem Critical role of RAAS modulation: Mechanisms and insights RAAS blockade: Focus on ACEI Beyond current strategies: Focus on angiotensin
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationANGIOTENSIN-CONVERTING
BRIEF REPORT Impact of on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure Catherine Demers, MD, MSc John J. V. McMurray, MD Karl Swedberg, MD, PhD Marc A. Pfeffer,
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More information